目标导向骨质疏松治疗:骨密度目标是否有效?
本文评述美国骨与矿物质研究学会(ASBMR)2024年工作组提出的以骨密度(BMD)目标为导向的骨质疏松治疗框架。作者指出,支持该框架的两项关键证据——治疗中BMD越高骨折风险越低、以及BMD增幅与骨折风险降幅相关的荟萃回归——可能存在推断缺陷。因此,现有证据不支持将BMD治疗目标用于骨质疏松管理,频繁BMD监测会增加成本而无明确获益。
要点
- 治疗中BMD主要反映基线BMD对骨折风险的影响,而非治疗中BMD变化的效果。
- BMD增幅与骨折风险降幅的荟萃回归关系依赖低效治疗,高效抗骨吸收药间未见此关系。
- 地舒单抗与唑来膦酸BMD效应不同但抗骨折疗效相似,不支持为达BMD目标而用地舒单抗。
核心结论
- 现有证据不支持在骨质疏松管理中使用BMD治疗目标。
- 目标导向框架要求的频繁BMD测量会增加成本而无明确获益。
研究设计与样本
- 本文为对ASBMR 2024年工作组目标导向骨质疏松治疗概念的评述性文章,非原始研究。
主要发现
- 在同时考虑基线BMD与治疗中BMD变化的研究中,治疗中BMD的影响主要反映基线BMD对骨折风险的作用。
- BMD增幅与骨折风险降幅的荟萃回归关系高度依赖纳入低效治疗,高效抗骨吸收药间未见此关系。
- 地舒单抗对BMD的效应大于唑来膦酸,但两者在试验中抗骨折疗效相似。
关键数值与推荐
- ASBMR 2024年工作组确定目标导向管理应包括治疗期间特定BMD目标,以确保最佳骨折风险降低。
临床怎么用
- 临床不应以BMD治疗目标作为骨质疏松管理依据,避免为目标而频繁测量BMD。
局限性
- 本文为评述性文章,未报告原始研究数据、样本量或P值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Over the last decade, goal-directed management of osteoporosis has been developed as a concept. In 2024, a working group of the American Society for Bone and Mineral Research (ASBMR) determined that this concept should include specific bone mineral density (BMD) targets during treatment, to ensure optimal fracture risk reduction. Two observations were key to this recommendation: that higher on-treatment BMDs are associated with lower fracture risks in several studies, and that, in a meta-regression of individual clinical trials, agents producing larger increases in BMD also produced greater reduction in fracture risk. However, the inferences drawn from these studies might be unsound. First, on-treatment BMD is the sum of baseline BMD and its change on therapy. In trials in which these variables have both been considered, it was found that the influence of on-treatment BMD is substantially a reflection of the effect of baseline BMD on fracture risk rather than an effect of on-treatment BMD change. Second, the meta-regression findings are heavily dependent on the inclusion of less effective treatments in the analysis. Among more effective antiresorptives, no such relationship is seen. For example, although denosumab has greater effects on BMD than zoledronate, these agents have similar anti-fracture efficacy in trials. Therefore, a key conclusion of the treat-to-BMD-target framework-that denosumab is needed for many patients to reach their BMD targets-has no clinical trial support, suggesting the framework is flawed. Thus, use of BMD treatment targets in osteoporosis management is not supported by available evidence, so the frequent BMD measurements required by the treat-to-target framework will increase costs without demonstrable benefit.
引用
- Reid IR. Goal-directed osteoporosis treatment: are bone mineral density targets valid? Lancet Diabetes Endocrinol. 2026. PMID: 42419342. doi:10.1016/S2213-8587(26)00123-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。